Navigation Links
The Market for Non-Small-Cell Lung Cancer (NSCLC) Will Grow to $7 Billion in 2022, Fuelled by the Entry of Twelve Novel Agents
Date:12/12/2013

BURLINGTON, Mass., Dec. 12, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the entry of twelve new therapies into the non-small-cell lung cancer (NSCLC) drug market will drive the market's growth from $4.9 billion in 2012 to over $7 billion in 2022. The approval of three immunotherapies, the entry of second generation ALK and EGFR inhibitors, as well as continued uptake of Pfizer's Xalkori and EGFR inhibitors particularly in the advanced/metastatic first-line treatment setting will drive the growth of the NSCLC drug market. This market growth will occur despite the generic erosion of key branded current therapies including Eli Lilly's Alimta and Genentech/Roche/Chugai/Astellas's Tarceva.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

The Pharmacor Non-Small-Cell Lung Cancer advisory service also finds that treatment of NSCLC is becoming increasingly personalized, driven by the accumulation of positive data of current and novel therapies in molecularly defined populations. The expected approvals of Novartis's ceritinib (LDK-378) and Chugai/Roche's alectinib for Xalkori-treated patients further advances the personalized treatment approach in NSCLC, offering a targeted second-line standard-of-care therapy for ALK-translocation positive patients.

"The majority of the agents in the NSCLC pipeline are being developed to target specific molecular targets," said Decision Resources Business Insights Analyst Orestis Mavroudis-Chocholis, Ph.D. "In the next ten years, we expect the launch of seven agents positioned to treat specific molecularly defined patient subpopulations—Pfizer's dacomitinib, Genentech/Roche/Chugai's onartuzumab, ceritinib, alectinib, Bristol-Myers Squibb/Ono Pharmaceutical's nivolumab, Merck's MK-3475 (formerly known as lambrolizumab) and AstraZeneca's selumetinib."

The report also finds that the unmet needs for more efficacious therapies for squamous-cell NSCLC patients and those harboring KRAS mutations will be addressed to some extent by the approval of novel therapies, Eli Lilly's necitumumab and selumetinib, respectively. However, significant unmet need remains particularly for these underserved patient populations.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group

Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Rapid Fire Marketing Funds Development of Second Generation Vapor Inhaler
2. ulrich medical USA™ Releases New Expandable Spinal Implant for US Market
3. Nektar to Announce Financial Results for the First Quarter of 2012 on Wednesday, May 2, 2012, After Close of U.S.-Based Financial Markets
4. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
5. International Drug & Explosives Detection Company IDenta Corp. Releases Information to OTC markets.
6. Althea Technologies Appoints Dr. Kristin DeFife, Director, Biologics Manufacturing And Jack Wright, VP, Sales and Marketing
7. Ophthalmic Drugs: World Market Prospects 2012-2022
8. OTC Pharmaceuticals: Global Industry Almanac, MarketLine
9. ResearchMoz: The World Anesthesia Drug Market (General, Local, Adjunctive) - Market Research Report
10. Endocrinology Market to 2018 - Advanced Injection Devices for Growth Hormone and Somatostatin will Improve Ease of Use for Patients
11. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... 24, 2017 Research and Markets has ... 2017-2027" report to their offering. ... The Cell Therapy Manufacturing Market, ... market of cell therapy manufacturing and focuses both on contract ... therapies are anticipated to emerge as viable alternatives to conventional ...
(Date:3/24/2017)... Research and Markets has announced the addition of ... Forecast to 2022" report to their offering. ... The global wound care market was worth $24,482.9 ... of 6.7% during 2016-2022 Among the various wound care products ... the global market in 2015. Among the various applications, surgical wound segment ...
(Date:3/24/2017)... NEW YORK , March 24, 2017 ... ... Research, a leading publisher of cannabis market research, the legal ... 27 percent CAGR through 2021, despite conflicting signals from the ... Analytics, points out that the two biggest drivers of growth ...
Breaking Medicine Technology:
(Date:3/24/2017)... , ... March 24, 2017 , ... ... which will spark a conversation on the current obstacles facing infection prevention and ... completely preventable deaths caused by these infections. , The print component of ...
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... According to ... score is invalid because it does not obey the rules Congress has directed the ... equivalent jobs, which the GOP reform would restore. Yet, it estimates a reduction in ...
(Date:3/24/2017)... Arizona (PRWEB) , ... March 24, 2017 , ... ... Healing Center, Sedona, Arizona’s Premier Center for Shamanic Healing and Spiritual Awakening, ... Luis Delgado, June 9--24, 2017. This sacred and spiritual journey during the ...
(Date:3/24/2017)... ... March 24, 2017 , ... On June 9, 2017, ... Claims Litigation seminar in Chicago, Illinois. She will present on: , Filing ... litigated under ERISA involve claims for long-term disability benefits. This session will ...
(Date:3/24/2017)... Texas (PRWEB) , ... March 24, 2017 , ... ... 2017 the year of enhancements, upgrading their training and leads programs. , In ... University. Reserved for elite sales agents, Performance Partners is designed to teach how ...
Breaking Medicine News(10 mins):